Ulcerative Colitis | Treatment Algorithms: Claims Data Analysis | Pediatric | US | 2025

Ulcerative colitis (UC) is a chronic intermittent relapsing disorder of the large intestine and rectum. Children with UC have a more-complicated disease course compared with adult patients. Treatment typically begins with conventional agents (e.g., 5-aminosalicylic acids [5-ASAs]) that are often effective for patients with mild to moderate disease. Treatment then progresses to more-potent drugs, such as immunosuppressants and/or biologics, as needed. Among the biologics, tumor necrosis factor (TNF)-alpha inhibitors (Johnson & Johnson Innovative Medicine’s Remicade and AbbVie’s Humira) are first-line biological therapies for pediatric UC. Non-TNF biologics, including Takeda’s Entyvio, Johnson & Johnson Innovative Medicine’s Stelara, Eli Lilly’s Omvoh, and Johnson & Johnson Innovative Medicine’s Tremfya, may be used off-label for pediatric UC. Other drugs approved for adult UC are in clinical trials for pediatric UC and may offer promising alternatives, particularly after anti-TNF failure.

Questions answered

• What patient shares do key therapies and brands garner by line of therapy in newly diagnosed pediatric UC patients? What are the quarterly trends in prescribing among recently treated and newly diagnosed pediatric UC patients?
• How have Entyvio and Stelara been integrated into the treatment algorithm, and what are their sources of business?
• What percentage of pediatric UC patients receive drug therapy within 365 days of diagnosis, and how quickly? What percentage of patients progress to later lines of therapy within 365 days of diagnosis?
• What percentage of pediatric UC patients are treated with monotherapy vs. combination therapy? What are the most commonly used combinations?
• What are the product-level compliance and persistency rates among drug-treated patients?

Market covered: United States

Key companies: AbbVie, Johnson & Johnson Innovative Medicine, Pfizer, Takeda, BMS.

Key drugs: Humira, Remicade, biosimilar infliximab, Entyvio, Stelara, Xeljanz / Xeljanz XR, Simponi, Zeposia, Rinvoq, Omvoh, Skyrizi, aminosalicylates, immunosuppressants.

Product description

Treatment Algorithms: Claims Data Analysis provides detailed, quantitative analysis of the treatment journey and brand usage across lines of therapy and overall using real-world, patient-level claims data, enabling you to:

• Understand patient flow between lines of therapy.
• Evaluate your brand share against competitors.
• Accurately assess your source of business.
• Quantify opportunities at different stages of the treatment algorithm.

Key feature

Dashboard featuring interactive visuals, easy navigation, and expanded analyses